Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings

Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings

Introduction Neoadjuvant chemoimmunotherapy has achieved overall survival (OS) benefit for patients with resectable non-small cell lung cancer (NSCLC). Here, we present outcomes after 3 years of follow-up from the first reported study of neoadjuvant atezolizumab+chemotherapy.Methods This open-label,...

Full description

Saved in:
Bibliographic Details
Main Authors: Benjamin Izar, Justin F Gainor, Mark M Awad, Codruta Chiuzan, Anjali Saqi, Catherine A Shu, Katja Schulze, Brian S Henick, Naiyer A Rizvi, Samyukta Mallick, Yohanna Georgis, Peter D Koch, Stephanie Izard, Robert F Garofano, Cheryl V Wong, Jessica Grindheim, Joshua R Sonett, Alison M Taylor
Format: Article
Language:English
Published: BMJ Publishing Group 2024-12-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/12/e009301.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/12/e009301.full

Similar Items